Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study
Pfister, Christian, Gravis, Gwenaelle, Flechon, Aude, Chevreau, Christine, Mahammedi, Hakim, Laguerre, Brigitte, Guillot, Aline, Joly, Florence, Soulie, Michel, Allory, Yves, Harter, Valentin, Culine, Stéphane, PIGNOT, Géraldine, FENDLER, Jean Philippe, GUY, Laurent, VERHOEST, Grégory, MOTTET, Nicolas, DOERFLER, Arnaud, ABADIE LACOURTOISIE, Sophie, AZZOUZI, Abde Rahmene, MONGIAT, Pierre, GEOFFROIS, Lionnel, ESCHWEGE, Pascal, DI FIORE, Frédéric, ROUBAUD, Guilhem, HOEPFFNER, Jean Luc, BARTHELEMY, Philippe, LANG, Hervé, VOOG, Eric, MANDRON, Eric, TOURANI, Jean Marc, SERRATE, Camille, COLAU, Alexandre, SALDANA, Carolina, DE LA TAILLE, Alexandre, NGUYEN, Thierry, KLEINCLAUSS, François, LORIOT, Yohan, IRANI, Jacques, EYMARD, Jean Christophe, LARRE, Stéphane, HUILLARD, Olivier, ZERBIB, Marc, ROLLAND, Frédéric, RIGAUD, Jérôme, HOUEDE, Nadine, DROUPY, Stéphane, MALOUF, Georgina, ROUPRET, Morgan, VIEILLOT, Sabine, LETANG, Nicolas, LHARIDON, Tiffen, GASCHIGNARD, Nicolas, HILGERS, Werner, DAVIN, Jean Louis
Published in The lancet oncology (01.02.2024)
Published in The lancet oncology (01.02.2024)
Get full text
Journal Article